Nexalin Technology, Inc. is a Houston, Texas-based medical device company focused on designing and developing innovative neurostimulation products to address the global mental health crisis. The company's primary product, the Nexalin Device, provides a non-invasive and drug-free treatment for anxiety and insomnia by emitting a proprietary frequency-based waveform that stimulates ...Nexalin Technology, Inc. is a Houston, Texas-based medical device company focused on designing and developing innovative neurostimulation products to address the global mental health crisis. The company's primary product, the Nexalin Device, provides a non-invasive and drug-free treatment for anxiety and insomnia by emitting a proprietary frequency-based waveform that stimulates mid-brain structures associated with psychological disorders. With a mission to disrupt the traditional mental health treatment industry, Nexalin aims to offer safe, effective, and affordable alternatives to pharmaceuticals. The company is currently developing 'Generation 2,' a next-generation device undergoing clinical trials to treat broader conditions such as opiate addiction, chronic pain, Alzheimer's disease, and dementia. Founded in 2010 by John Patrick Claude, Nexalin went public on the NASDAQ Capital Market in September 2022. The company has a small workforce of 8 employees, reflecting its early-stage nature. Financially, Nexalin is pre-revenue or has minimal revenue, with a market cap of approximately $7.7 million, and is investing heavily in R&D and clinical trials. Key executives include CEO Mark White, who has over 30 years of entrepreneurial experience, and CFO Justin Van Fleet. The company's financial metrics indicate negative profitability and cash flow, typical for a clinical-stage medical device firm. Despite operating losses, Nexalin maintains a strong focus on innovation and clinical validation, aiming to bring transformative treatments to market. The company's stock trades on NASDAQ under the symbol NXL, and it continues to seek partnerships and regulatory approvals to commercialize its technology.
